Pfizer and BioNTech to Supply EU with 100 Million Additional COVID-19 Vaccine Doses

April 19, 2021
BioPharm International Editors

The additional doses are a result of the European Commission’s expanded advance purchase agreement, which brings the total number of doses delivered to the EU to 600 million.

Pfizer and BioNTech announced on April 19, 2021 that they will supply an additional 100 million doses of their COVID-19 vaccine, COMIRNATY, to the European Union (EU) member states in 2021.

The additional doses are a result of the European Commission’s (EC) expanded advance purchase agreement, which brings the total number of doses delivered to the EU to 600 million, Pfizer said in a company press release.

“We remain committed to moving as quickly and safely as possible to bring this vaccine to more people in Europe, as the deadly virus continues to wreak havoc across the continent.” said Albert Bourla, chairman and CEO, Pfizer, in the press release. “To date, we have met all of our supply commitments to the EC and we plan to deliver 250 million doses to the European Union in Q2 [second quarter], a four-fold increase on Q1’s [first quarter’s] agreed quantity.”

“The additional 100 million doses from this option exercise will further help to support the acceleration of the vaccination campaigns throughout the EU. We now intend to deliver a total of 600 million doses to the EU this year, which covers two thirds of the EU population and represents the largest cumulative supply agreement for COMIRNATY that we have agreed to date globally,” added Sean Marett, chief business and chief commercial officer, BioNTech, in the press release.

Source: Pfizer